Physician profile
Pradip P Jamnadas
NPI 1710987946
$7,972.80
in general payments reported to CMS, 2019-2025
50 companies · $955 in 2025
The $955 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $499 · 2021: $1,599 · 2022: $1,233 · 2023: $905 · 2024: $1,100 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.57 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $751.72 | 2019-2025 | |
| Abbott Laboratories | $695.86 | 2019-2025 | Aveir, Freestyle Libre 3, Mitraclip |
| Tosoh Bioscience, INC. | $639.00 | 2019 | |
| Impulse Dynamics (USA) INC. | $449.39 | 2021-2025 | Optimizer, Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $396.53 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $365.49 | 2022-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $359.22 | 2021-2024 | Verquvo |
| Amgen INC. | $347.52 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $316.44 | 2019-2025 | |
| Heartflow, INC. | $283.06 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $263.59 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $248.10 | 2019-2025 | Uptravi |
| Biotronik INC. | $239.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.91 | 2020-2024 | Jardiance |
| Cvrx, INC. | $204.99 | 2021-2025 | Barostim Neo System |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradip Jamnadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.